In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on PharmaCyte Biotech (PMCB – Research Report). The company’s shares closed last Tuesday at $2.36, close to its 52-week low of $1.79.
According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -16.5% and a 26.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.
PharmaCyte Biotech has an analyst consensus of Hold.
Based on PharmaCyte Biotech’s latest earnings release for the quarter ending October 31, the company reported a quarterly GAAP net loss of $979.7K. In comparison, last year the company had a GAAP net loss of $757.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.
Read More on PMCB:
- Anaplan to be Taken Private; What Should Investors do Now?
- Nielsen Holdings Stands Tall on Strong Growth Projections
- Merger Between BitNile Holdings’ Subsidiaries Doubles Stock Price
- H.C. Wainwright Reiterates Their Buy Rating on Nuvectis Pharma (NVCT)
- ServiceNow: Impressive Free Cash Flow Growth, Still Overpriced